about
Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar.Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Drug utilization pattern and cost for the treatment of severe sepsis and septic shock in critically ill cancer patients.Protein Binding of First-Line Antituberculous Drugs.Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in QatarPerspectives for personalized therapy for patients with multidrug-resistant tuberculosisMetoclopramide-induced asystolic cardiac arrestEvaluating the effectiveness and safety of hydrocortisone therapy in cancer patients with septic shockA Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C TreatmentEvaluation of super-boosted lopinavir/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosisFluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose SelectionCycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
P50
Q36268159-09C92E93-62B3-41D7-A59D-BCFD406BF421Q38197844-D0CD76DB-DF60-4DF5-9F61-E1BA21A7A7E3Q40095703-F493FF4C-DE64-410E-9F08-AEB11B83CDD1Q46831676-9CC1E6F9-F0E7-4CC6-A218-4B339F65CD71Q54218957-5E922F1E-9C71-428B-A025-BF28A6101513Q54245604-0E35B8FF-70CA-4B9A-8AAB-DAD527C28EAEQ56334454-2FF5E94D-76D2-46F5-B48E-33244ACDEC1DQ58321449-5F92F3EE-7F05-40B0-90B6-FE8671B44A84Q87109326-B7AE62A1-8222-411D-A446-506C5C17BE3AQ87781645-54D1482D-AD2A-4213-A3F5-505C7476DC07Q90572975-D1A5BEFD-CA1D-4A89-94C1-DBCC5C0D2F99Q91194843-321F93BC-4D76-4D2D-BC8D-EBA83901E023Q91803528-7780660E-B12E-48B9-86CA-E5509EF7C902Q92282296-D2554BE7-C967-4D45-91BB-BCCD2BD18285
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mohammad H Al-Shaer
@ast
Mohammad H Al-Shaer
@en
Mohammad H Al-Shaer
@es
Mohammad H Al-Shaer
@nl
type
label
Mohammad H Al-Shaer
@ast
Mohammad H Al-Shaer
@en
Mohammad H Al-Shaer
@es
Mohammad H Al-Shaer
@nl
prefLabel
Mohammad H Al-Shaer
@ast
Mohammad H Al-Shaer
@en
Mohammad H Al-Shaer
@es
Mohammad H Al-Shaer
@nl
P106
P31
P496
0000-0003-1432-5175